<DOC>
	<DOCNO>NCT00060528</DOCNO>
	<brief_summary>Background : `` Adenocarcinoma prostate common cancer diagnosis American male follow lung cancer lead cause cancer death. `` Vaccine strategy represent novel therapeutic approach treatment prostate cancer . One potential target prostate cancer vaccine prostatic specific antigen ( PSA ) , due restrict expression prostate cancer normal prostatic epithelial cell . Objectives : `` The primary objective determine impact granulocyte-macrophage colony stimulate factor ( GM-CSF ) recombinant fowlpox granulocyte-macrophage colony stimulate factor ( rF-GM-CSF ) immunologic response patient treat vaccines. `` Secondary - determine change prostatic specific antigen ( PSA ) -specific T cell patient treat vaccine use enzyme link immunosorbent spot ( ELISPOT ) assay analysis. `` To document objective anti-tumor response may occur . Eligibility : `` Patients must androgen insensitive metastatic prostate cancer. `` All patient receive progressed hormonal therapy. `` Must objective evidence metastasis relapse local disease . Therefore , must rise PSA least one following : positive bone scan , palpable disease , positive imaging studies. `` Must life expectancy 6 month Eastern Cooperative Oncology Group ( ECOG ) status 0 2 . `` Patients must human leukocyte antigen serotype within HLA-A A serotype group ( HLA-A2+ ) . `` Granulocyte count great equal 1,500/mm^3 , Platelet great equal 100,000/mm^3 , hemoglobin ( Hgb ) great equal 10Gm/dL , Lymphocyte count great equal 500/mm^3 ; Bilirubin le 1.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 2.5x upper limit normal ( ULN ) , Creatinine Clearance great equal 60 `` No significant cardiac disease , significant pulmonary disease , serious inter-current medical illness . Design : `` Cohorts three , four five provide safety data combine cohort two rGM-CSF well two dos rFGM-CSF respectively . `` This study conduct small , randomize pilot study compare immunologic effect vaccine strategy alone , recombinant granulocyte-macrophage colony stimulate factor ( GM-CSF ) , either 2 dos fowlpox-GM-CSF . `` This study consist 4 randomized arm 8 patient , HLA-A2+ . The maximum accrual trial 62 .</brief_summary>
	<brief_title>Sequential Vaccinations Prostate Cancer Patients</brief_title>
	<detailed_description>Background : - Adenocarcinoma prostate common cancer diagnosis American male follow lung cancer lead cause cancer death . - Vaccine strategy represent novel therapeutic approach treatment prostate cancer . One potential target prostate cancer vaccine prostatic specific antigen ( PSA ) , due restrict expression prostate cancer normal prostatic epithelial cell . Objectives : - The primary objective determine impact granulocyte-macrophage colony stimulate factor ( GM-CSF ) recombinant fowlpox granulocyte-macrophage colony stimulate factor ( rF-GM-CSF ) immunologic response patient treat vaccine . - Secondary - determine change prostatic specific antigen ( PSA ) -specific T cell patient treat vaccine use enzyme link immunosorbent spot ( ELISPOT ) assay analysis . - To document objective anti-tumor response may occur . Eligibility : - Patients must androgen insensitive metastatic prostate cancer . - All patient receive progressed hormonal therapy . - Must objective evidence metastasis relapse local disease . Therefore , must rise PSA least one following : positive bone scan , palpable disease , positive imaging study . - Must life expectancy 6 month Eastern Cooperative Oncology Group ( ECOG ) status 0 2 . - Patients must HLA-A2+ . - Granulocyte count great equal 1,500/mm^3 , Platelet great equal 100,000/mm^3 , hemoglobin ( Hgb ) great equal 10Gm/dL , Lymphocyte count great equal 500/mm^3 ; Bilirubin le 1.5mg/dL , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 2.5x upper limit normal ( ULN ) , Creatinine Clearance great equal 60 - No significant cardiac disease , significant pulmonary disease , serious inter-current medical illness . Design : - Cohorts three , four five provide safety data combine cohort two rGM-CSF well two dos rFGM-CSF respectively . - This study conduct small , randomize pilot study compare immunologic effect vaccine strategy alone , recombinant GM-CSF , either 2 dos fowlpox-GM-CSF . - This study consist 4 randomized arm 8 patient , HLA-A2+ .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histopathological documentation prostate cancer confirm Laboratory Pathology , Center Cancer Research ( CCR ) , National Cancer Institute ( NCI ) , National Naval Medical Center ( NNMC ) prior start study . If pathologic specimen available NCI NNMC , patient may enroll pathologist 's report show histologic diagnosis prostate cancer clinical course consistent disease . Patients must androgen insensitive metastatic prostate cancer . Progression must document least one follow parameter : 1 . All patient must receive standard care ( hormonal ) treatment enter trial . 2 . All patient receive progressed hormonal therapy metastatic prostate carcinoma . 3 . All subject must objective evidence metastasis relapse local disease eligible Phase I trial ; therefore , must rise PSA least one following : positive bone scan , palpable disease , positive imaging study , define . . Two consecutively rise prostatic specific antigen ( PSA ) level , separate least 1 week , least one measurement 50 % nadir reach last therapeutic maneuver ( long last measurement 5 ng/ml great ) , ii . At least one lesion consistent metastatic cancer Technetium ( Tc ) 99 whole body scintigraphy , and/or iii . Softtissue metastases measure appropriate modality ( i.e. , image , palpation ) . Patients must life expectancy 6 month . Patients must performance status 0 2 accord Eastern Cooperative Oncology Group ( ECOG ) criterion . Patients must recover acute toxicity relate prior therapy , include surgery , radiation ( treatment must complete least 4 week prior eligible study ) . Patients respond hormonal therapy eligible evidence disease progression . Hematological eligibility parameter ( within 16 day start therapy ) : Granulocyte count great equal 1,500/mm^3 Platelet count great equal 100,000/mm^3 Lymphocyte count great equal 500/mm^3 Hemoglobin ( Hgb ) great equal 10 Gm/dL Biochemical eligibility parameter ( within 16 day start therapy ) : 1 . A 24hour urine collection baseline measure creatinine clearance ( CrCl ) , protein electrolyte . CrCl great 60 , proteinuria less 1000 milligram per 24 hour , less equal Grade 1 ( NCIcommon toxicity criterion ( CTC ) version 2.0 ) proteinuria , Grade 0 hematuria , abnormal sediment . Grade 0 creatinine . Patients must serum creatinine within normal limit . Any abnormality sediment presence hematuria without likely underlying cause prompt investigator consider evaluation nephrologist evidence underlie renal pathology . Patients may eligible underlie cause abnormality determine nonrenal . 2 . Hepatic function : Bilirubin le 1.5 mg/dl , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) less 2.5 time upper limit normal . 3 . Patients must test negative human immunodeficiency virus ( HIV ) , Hepatitis B C. Patients must active malignancy within past 2 year ( exception nonmelanoma skin cancer carcinoma situ bladder ) life threaten illness . Patients must willing travel National Institutes Health ( NIH ) followup visit . Patients must great equal 18 year age . All patient receive prior vaccination vaccinia virus ( smallpox immunization ) must history allergy untoward reaction vaccine . Since vaccinia immunoglobulin ( VIG ) available Centers Disease Control ( CDC ) , prior vaccinia vaccination safety precaution longer require . Patients must understand sign inform consent explain neoplastic nature disease , procedures follow , experimental nature treatment , alternative treatment , potential risk toxicity , voluntary nature participation . Patients must receive follow chemotherapeutic agent cancer within 3 year enrol study : docetaxel , paclitaxel , doxorubicin , cisplatinum , carboplatinum , mitoxantrone , estramustine , cyclophosphamide , irinotecan , topotecan . Patients must receive prior PSA vaccine therapy . Patients test human leukocyte antigen serotype within HLAA A serotype group ( HLAA2 ) . This test may draw patient 's refer physician time referral ( see Appendix C , HLAtyping consent ) . This consent mail patient discuss patient . The signed consent sign witness , mail assign research nurse NIH Clinical Center . These patient must measurable disease compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , bone scan . The effect study agent use protocol develop human fetus unknown . For reason men must agree use adequate contraception prior study entry duration study participation . INCLUSION CRITERIA : Patients must histopathological documentation prostate cancer confirm Laboratory Pathology , Center Cancer Research ( CCR ) , National Cancer Institute ( NCI ) , National Naval Medical Center ( NNMC ) prior start study . If pathologic specimen available NCI NNMC , patient may enroll pathologist 's report show histologic diagnosis prostate cancer clinical course consistent disease . 1 . All patient receive progressed hormonal therapy metastatic prostate carcinoma . 2 . All subject must objective evidence metastasis relapse local disease eligible ; therefore , must rise PSA least one following : positive bone scan , palpable disease , positive imaging study , define . . Two consecutively rise PSA level , separate least 1 week , least one measurement 50 % nadir reach last therapeutic maneuver ( long last measurement 5 ng/ml great ) , ii . At least one lesion consistent metastatic cancer Technetium ( Tc ) 99 whole body scintigraphy , and/or iii . Softtissue metastases measure appropriate modality ( i.e. , image , palpation ) . Patients must life expectancy 6 month . Patients must performance status 0 2 accord ECOG criterion . Patients must recover acute toxicity relate prior therapy , include surgery , radiation ( treatment must complete least 4 week prior eligible study ) . Hematological eligibility parameter ( within 16 day start therapy ) : Granulocyte count great equal 1,500/mm^3 Platelet count great equal 100,000/mm^3 Lymphocyte count great equal 500/mm^3 Hgb great equal 10 Gm/dL Biochemical eligibility parameter ( within 16 day start therapy ) : 1 . A 24hour urine collection baseline measure creatinine clearance ( CrCl ) , protein electrolyte . CrCl great 60 proteinuria less 1000 milligram per 24 hour , less equal Grade 1 ( NCICommon Toxicity Criteria ( CTC ) version 2.0 ) proteinuria , Grade 0 hematuria , abnormal sediment . Grade 0 creatinine . Patients must serum creatinine within normal limit . Any abnormality sediment presence hematuria without likely underlying cause prompt investigator consider evaluation nephrologist evidence underlie renal pathology . Patients may eligible underlie cause abnormality determine nonrenal . 2 . Hepatic function : Bilirubin le 1.5 mg/dl , AST ALT less 2.5 time upper limit normal . 3 . Patients must test negative HIV , Hepatitis B C. Patients must active malignancy within past 2 year ( exception nonmelanoma skin cancer carcinoma situ bladder ) life threaten illness . Patients must willing travel NIH followup visit . Patients must great equal 18 year age . All patient receive prior vaccination vaccinia virus ( smallpox immunization ) must history allergy untoward reaction vaccine . Since vaccinia immunoglobulin ( VIG ) available CDC , prior vaccinia vaccination safety precaution longer require . Patients must understand sign inform consent explain neoplastic nature disease , procedures follow , experimental nature treatment , alternative treatment , potential risk toxicity , voluntary nature participation . Patients receive follow chemotherapeutic agent cancer within 3 year enrol study : docetaxel , paclitaxel , doxorubicin , cisplatinum , carboplatinum , mitoxantrone , estramustine , cyclophosphamide , irinotecan , topotecan . Patients receive prior PSA vaccine therapy . All patient test HLAA2 . Patients must HLAA2+ . This test may draw patient 's refer physician time referral ( see Appendix C , HLAtyping consent ) . This consent mail patient discuss patient . The signed consent sign witness , mail assign research nurse National Institutes Health ( NIH ) Clinical Center . These patient must measurable disease compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , bone scan . The effect study agent use protocol develop human fetus unknown . For reason men must agree use adequate contraception prior study entry duration study participation . EXCLUSION CRITERIA : Prior splenectomy . Concurrent steroid use , except topical steroid inhale steroid use . The recombinant vaccinia vaccine administer follow apply either recipient , least 3 week vaccination , close household contact : person active history eczema eczematoid skin disorder ; acute , chronic exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne open rash wound ) condition resolve ; pregnant nursing woman ; child 5 year age ; immunodeficient immunosuppressed person ( disease therapy ) , include HIV infection . Close household contact share housing close physical contact . Patients know allergy egg . Other serious intercurrent illness . Patients brain metastasis . Patients history unstable newly diagnose angina pectoris , recent myocardial infarction ( within 6 month enrollment ) New York Heart Association class IIIV congestive heart failure . Patients antiandrogen therapy must undergo antiandrogen withdrawal least 4 week still show evidence rise PSA . Following treatment bicalutamide , patient must undergo withdrawal least 6 week still show evidence rise PSA . Prior treatment vaccine express PSA NOT eligible . Patients significant autoimmune disease active potentially life threaten activate . Patients clinically significant cardiomyopathy require treatment exclude protocol eligibility time .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Immune Assays</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>